Top Markets
#1 Nesa Nesa +790.47%
#2 Cortex Cortex +68.40%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.57%
#4 QuantixAI QuantixAI +23.51%
#5 EXOD EXOD +22.78%
#6 BSquared Network BSquared Network +20.12%
#7 Pons Pons +16.84%
#8 Instadapp Instadapp +16.15%
#9 OpenEden OpenEden +14.69%
#10 The Black Bull The Black Bull +13.93%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Caliway Biopharmaceuticals Co. L Caliway Biopharmaceuticals Co. L

Caliway Biopharmaceuticals Co. L

6919
Rank in Stocks #3556
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Share Price
$3.28
Last synced: 2026-07-31
Market Cap
$5.10B
Change (1 day)
0.00%
Change (1 year)
-49.70%
Country
TW
Trade Caliway Biopharmaceuticals Co. L (6919)

Category

Healthcare
P/E ratio for Caliway Biopharmaceuticals Co. L (6919)
P/E ratio as of 2026 TTM: 0
According to Caliway Biopharmaceuticals Co. L latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Caliway Biopharmaceuticals Co. L from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.